Matthew M. Gubin, Ph.D.
Areas of Research
Using both transplant tumor models and genetically engineered mouse models of primary and metastatic cancer, the Gubin lab seeks to better understand the process of immunoediting during metastasis and develop novel treatment strategies effective against primary and metastatic tumors.
Our lab has several highly-integrated projects towards the goal of making cancer immunotherapy safer, more specific and more effective to increasing numbers of patients. These studies include:
a) Defining T cell responses to tumor-specific neoantigens and tumor-associated antigens in primary, as well as metastatic tumors
b) Development of tumor neoantigen-specific vaccines (used alone or in combination with other therapies) effective against primary and metastatic cancers
c) Understanding transcriptional regulation of anti-tumor cytotoxic CD8+ T cells
d) High dimensional analyses (e.g., CyTOF and single-cell RNA sequencing) of intratumoral immune cells to better define successful and unsuccessful immunotherapies in metastatic cancers.